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Targeting a therapeutic LIF transgene to muscle via
the immune system ameliorates muscular
dystrophy
Steven S. Welc 1,5, Ivan Flores2,5, Michelle Wehling-Henricks1, Julian Ramos1, Ying Wang2, Carmen Bertoni3 &
James G. Tidball 1,2,4
Many potentially therapeutic molecules have been identified for treating Duchenne muscular
dystrophy. However, targeting those molecules only to sites of active pathology is an obstacle
to their clinical use. Because dystrophic muscles become extensively inflamed, we tested
whether expressing a therapeutic transgene in leukocyte progenitors that invade muscle
would provide selective, timely delivery to diseased muscle. We designed a transgene in
which leukemia inhibitory factor (LIF) is under control of a leukocyte-specific promoter and
transplanted transgenic cells into dystrophic mice. Transplantation diminishes pathology,
reduces Th2 cytokines in muscle and biases macrophages away from a CD163+/CD206+
phenotype that promotes fibrosis. Transgenic cells also abrogate TGFβ signaling, reduce
fibro/adipogenic progenitor cells and reduce fibrogenesis of muscle cells. These findings
indicate that leukocytes expressing a LIF transgene reduce fibrosis by suppressing type 2
immunity and highlight a novel application by which immune cells can be genetically modified
as potential therapeutics to treat muscle disease.
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Over recent years, investigators have identified numerous,potentially-therapeutic molecules for the treatment ofDuchenne muscular dystrophy (DMD), a lethal and
incurable muscle-wasting disease. For example, systemic delivery
of therapeutic agents that can inhibit fibrosis (e.g., block TGFβ
function1–3), inhibit muscle wasting (e.g., myostatin blocking
molecules4), and increase numbers of muscle stem cells called
satellite cells (e.g., Klotho5) all reduce pathology in the mdx
mouse model of DMD. However, systemic delivery of any of these
molecules presents risks of unintended off-target effects which
provide an obstacle to their clinical application for the treatment
of DMD. In addition, the occurrence of muscle pathology is not
synchronized in DMD patients. The unpredictable timing and
severity of disease vary between muscles in a single individual at
any given time, and also vary between locations in a single
muscle6. Even if a therapeutic agent were specifically targeted to
dystrophic muscle, achieving delivery only when pathology is
active presents an additional challenge.
Nature has provided a naturally-occurring system for targeted
delivery of potentially-therapeutic molecules to dystrophic muscle
at stages of the disease when pathology is active. Coinciding with
the unpredictable ebb and flow of pathology in muscular dys-
trophy, inflammatory cells invade in numbers that coincide with
the magnitude of muscle pathology. Although the immune cell
infiltrate in dystrophin-deficient muscle is complex7–12, macro-
phages comprise the vast majority and they can reach con-
centrations that exceed 107 cells per pound of muscle at the peak
of mdx pathology7. They are also rich sources of regulatory
molecules that can amplify muscle damage but also promote
muscle repair and regeneration in muscular dystrophy7,13,14.
Thus, the introduction of therapeutic transgenes that are
expressed at elevated levels in activated macrophages or other
immune cells could provide a strategy for intrinsically-regulated
targeting of therapeutic molecules specifically to dystrophic
muscles at the time of active pathology and at levels that were
commensurate with the extent of pathology.
In this investigation, we test whether transplantation of bone
marrow cells (BMCs) into which we have introduced a leukemia
inhibitory factor (LIF) transgene controlled by the human CD11b
promoter reduces the pathology of mdx dystrophy. Although mdx
pathology is less severe than DMD pathology, they share the
pathological features of muscle inflammation and progressive
fibrosis that persist over the entire lifespan and impair muscle
function, reduce health and increase mortality. The CD11b pro-
moter was chosen to drive the therapeutic transgene because
CD11b is expressed at low or undetectable levels in myeloid
precursors, but at increasingly elevated levels during myeloid cell
differentiation and activation15–17. LIF was selected as a ther-
apeutic molecule to test this system because it is expressed by
macrophages and can influence muscle growth, fibrosis, and
inflammation during disease or following injury18–21. Our find-
ings show that this intervention significantly modifies intramus-
cular macrophage phenotype and reduces inflammation and
fibrosis of dystrophic muscle, thereby reducing pathology. Per-
haps more valuable, the findings indicate that inflammatory cells
can be exploited as natural vectors to deliver therapeutic trans-
genes for the treatment of chronic diseases in which there is a
significant inflammatory component.
Results
A CD11b regulated LIF transgene suppresses M2-biased mar-
kers. We generated mice with a LIF transgene under control of
the CD11b promoter (CD11b/LIF transgenic mice). Quantitative
PCR (QPCR) analysis of Cd11b mRNA levels confirmed that
Cd11b expression increased as BMCs differentiate into bone
marrow-derived macrophages (BMDMs) (Fig. 1a). Freshly-
isolated bone marrow mononuclear cells (BMMCs) from trans-
genic mice had a ~2.8-fold higher Lif expression compared to
wild-type (WT). After 9 days of culture, Lif expression was ~10-
fold higher in transgenic BMDMs than WT (Fig. 1b). Thus, LIF
transgene expression increased with increased CD11b promoter
activation as monocytes differentiate into mature macrophages.
Upon becoming fully-differentiated macrophages, the CD11b/LIF
transgene had an autocrine effect on macrophage phenotype,
increasing expression of Cd68 by ~31% and reducing Cd163 and
arginase-1 (Arg1) by 47% and 42%, respectively (Fig. 1c). CD68 is
present at high levels in macrophages that are biased to a pro-
inflammatory phenotype (M1-biased). Arginase and CD163 are
present in macrophages that are biased toward a pro-fibrotic and
reparative phenotype (M2-biased)22.
CD11b/LIF transgene reduces mdx muscle inflammation and
fibrosis. We assayed whether the expression of the CD11b/LIF
transgene affected mdx pathology, focusing on influences on
muscle inflammation and fibrosis. We confirmed elevated
expression of Lif in the tibialis anterior (TA) and diaphragm
muscles of transgenic mice (CD11b/LIF mdx mice) (Fig. 2a) and
observed that cells in inflammatory lesions in CD11b/LIF mdx
mice showed higher levels of LIF protein than non-transgenic
mice (Fig. 2b–d). However, sera from transgenic mice showed no
elevation in LIF protein assayed by ELISA (mean ± sem: WT/mdx
19.25 ± 1.85 and LIF/mdx 26.19 ± 4.86 pg/ml , n= 3 per data set,
P= 0.25; two-tailed t-test). We also found no significant differ-
ences in the concentrations of cytokines previously implicated in
influencing the pathology of muscular dystrophy (IFNγ, TNF, IL-
4, and IL-10) in the serum of transgenic mice, compared to non-
transgenic mice (Supplementary Fig. 1).
We assessed effects of the transgene on mdx pathology over the
course of the disease, sampling at the acute onset of pathology (1-
month-old), the period of successful regeneration (3-months-
old), and the late, progressive stage of pathology (12-months-old)
in TA muscles. Diaphragm muscles show a progressive pathology
following disease onset. The CD11b/LIF transgene reduced
numbers of macrophages expressing the pan-macrophage marker
F4/80 at the stages of pathology characterized by extensive,
muscle inflammation (1-month-old in TA; 12-months-old in
diaphragm) (Fig. 2e–g). The transgene also reduced numbers of
CD163+ macrophages at the acute onset of pathology in both TA
and diaphragm (Fig. 2h–j) but did not affect numbers of CD68+
macrophages in either muscle at any stage of the disease that we
tested (Supplementary Fig. 2).
We tested whether the CD11b/LIF transgene reduced collagen
accumulation in mdx muscles, which would be consistent with a
reduction in numbers or activity of CD163 macrophages that
promote fibrosis of dystrophic muscle23. Both the TA and
diaphragm showed significant reductions in collagen type 1 at the
acute onset of pathology, and the transgene completely abrogated
collagen type 1 accumulation in the TA muscle, at least until 12-
months-old (Fig. 2k–m). The CD11b/LIF transgene also reduced
accumulation of collagen type 1 in diaphragms (Fig. 2n–p) and
reduced accumulation of collagen types 3 and 5 in diaphragms at
late stages of pathology and reduced collagen type 5 in 3-month-
old TA muscles (Supplementary Fig. 3).
Because the CD11b/LIF transgene prevented collagen type 1
accumulation in TA muscles and collagen type 1 is primarily
responsible for increased muscle stiffness caused by fibrosis, we
assayed for changes in the passive mechanical properties of TA
muscles in CD11b/LIF transgenic mdx mice. We subjected TA
muscles to cyclic, dynamic loading using 20% strains at a 0.6/s
strain rate, which is within the physiological range. Lissajous
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figures obtained by measuring force–strain relationships showed
that muscle stiffness (indicated by the slope of the tangent to the
loading phase of each cycle) was significantly less in CD11b/LIF
transgenic mdx mice (Fig. 2q, r). In addition, the transgenic mdx
muscles showed less energy dissipation during each cycle of
loading (proportional to the area inside each hysteresis loop
during a cycle of loading/unloading) (Fig. 2q, s), indicating higher
mechanical efficiency in the CD11b/LIF transgenic muscles.
CD11b/LIF transgene does not impair muscle growth.
Although previous investigations showed that M2-biased mac-
rophages promote muscle fibrosis, they also promote
regeneration23,24. We tested this possibility by assaying for effects
of the transgene on TA muscle fiber cross-sectional area as an
index of regeneration and found no difference in TA fiber size
between transgenic and non-transgenic mdx mice at any age
sampled (Supplementary Fig. 4A). We also assayed for the pro-
portion of muscle fibers that expressed developmental myosin
heavy chain (dMHC), which is upregulated in regenerating fibers.
We observed a higher proportion of dMHC+ fibers in TAs of
CD11b/LIF transgenic mdx mice at 3-months-old and a trend for
more dMHC+ fibers at 1-month and 12-months-old, compared
to non-transgenic mdx mice (Supplementary Fig. 4B). Similarly,
the proportions of dMHC+ fibers in 3-months-old and 12-
months-old diaphragms were increased by the transgene (Sup-
plementary Fig. 4C). Collectively, these observations indicate that
the CD11b/LIF transgene does not impair muscle growth or
regeneration, despite the reduction of CD163+ cells.
Transplanted CD11b/LIF cells reduce inflammation. Our ana-
lyses of CD11b/LIF transgenic mdx mice showed that the trans-
gene reduces muscle inflammation and fibrosis, thereby
validating the transgene as a therapeutic molecule for muscular
dystrophy. However, our primary goal in the investigation was to
determine whether transplanted bone marrow derived cells
(BMDCs) could serve as vehicles to deliver therapeutic molecules
to dystrophic muscle through a clinically-relevant approach; in
particular, we questioned whether transplantation of genetically-
modified BMCs into dystrophic animals provides a strategy for
targeted delivery of therapeutic cargo to diseased muscle. We
assayed treatment effects in 6-months-old mdx mice at 4 months
post-bone marrow transplantation (BMT) for scientific and
technical reasons. First, we anticipated that a likely, beneficial
outcome of leukocyte delivery of a LIF transgene to muscle would
be reductions in fibrosis. Our previous work5 showed that 6-
months-old mdx muscles show significantly elevated
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Fig. 1 Differentiation of BMCs into macrophages increases CD11b/LIF transgene expression, causing suppression of M2-biased macrophage markers.
a QPCR data showing differences in the level of Cd11b expression in C57BL6 BMCs stimulated with MCSF and differentiated to macrophages for 3–9 days.
Values are normalized to 3-day cultures, n= 4 for each data set; * indicates significantly different from 3-day data set and # indicates significantly different
from 5- and 7-day data sets at P < 0.05. P-values based on ANOVA with Tukey’s multiple comparison test. For all histograms in the figure, the bars indicate
mean ± sem. b QPCR data showing increased Lif expression in freshly-isolated BMMCs and BMDMs cultured for 9 days from CD11b/LIF transgenic mice
compared to transgene negative littermate controls (WT). Data are presented as mean ± sem. BMCs were isolated from three independent donors, n= 3
per data set. * Indicates significantly different from WT at P < 0.05. P-values based on two-tailed t-test. F-test BMDMs day 9 (P= 0.0038). c QPCR
analysis shows that CD11b/LIF BMDMs have increased the expression of Cd68 and reduced the expression of Cd163 and Arg1. Data are presented as mean
± sem, n= 5 for each data set, n= 4 for WT BMDMs Inos, and CD11b/LIF BMDMs Arg1 data sets (P < 0.05). n.d. indicates that no expression was detected.
Data presented for BMDMs (b, c) were isolated from a single donor animal of each genotype and cultured as n= 5 technical replicates. Significant findings
were verified with biological replicates of experiments from independent donors. * Indicates significantly different from WT BMDMs at P < 0.05. P-values
based on two-tailed t-test. F-test Cd206 (P= 0.0258) and Il10 (P= 0.0311). Source data are provided as a Source Data file
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accumulation of type I and type III collagen. We also showed that
at 6-months-old, mdx limb muscles contain elevated numbers of
M2-biased macrophages that contribute to muscle fibrosis5. The
technical rationale for sampling at 6 months is that engraftment
of transplanted cells takes time and our preliminary experiments
showed that high levels of engraftment could be achieved by
4 months post-BMT.
At the time of tissue collection from transplant recipients,
circulating leukocytes were 86.6% donor-derived (sem= 1.14;
n= 25). QPCR of muscles showed that CD11b/LIF recipients
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(LIF BMT/mdx mice) had reduced expression of the M2-biased
markers Cd163, CD206 (Mrc1), and arginase-2 (Arg2) expression
by 51%, 49%, and 43%, respectively (Fig. 3a). This effect
resembles the autocrine effect of CD11b/LIF on macrophages
in vitro (Fig. 1c). Additionally, the transgene affected the
expression of Th2 cytokines associated with M2-biased macro-
phage activation, IL-4 (Il4) and IL-10 (Il10), which were reduced
by ~79% and ~84%, respectively (Fig. 3a). Reduced cytokine
expression was accompanied by a ~2.8-fold increase in the
expression of suppressor of cytokine signaling 3 (Socs3) in
CD11b/LIF BMT recipients (Fig. 3a). Socs3 expression is activated
by LIF25 and its elevation in muscles of CD11b/LIF BMT
recipients verifies an increase in LIF signaling in muscle.
We tested the effect of CD11b/LIF BMT on macrophage
numbers and phenotype because changes in macrophages have
profound effects on dystrophic muscle pathology7,13,14,26. We
performed immunohistochemistry using anti-F4/80, to identify
total macrophage populations, or anti-CD68 (M1-biased macro-
phages), anti-CD163 (M2-biased), or anti-CD206 (M2-biased).
Mdxmice that received CD11b/LIF BMCs had 37% fewer F4/80+
cells compared to mice receiving WT BMCs (Fig. 3b). Quantita-
tion of CD68+, CD163+ and CD206+ macrophages showed no
difference in CD68+ cells (mean ± sem: WT BMT/mdx 17,525 ±
1502 and LIF BMT/mdx 16,377 ± 1440 cells/mm3, n= 5 per data
set, P= 0.60; two-tailed t-test), a 32% reduction of CD163+ cells
(Fig. 3e) and 46% fewer CD206+ cells (Fig. 3h) in the dystrophic
muscle. However, numbers of CD4+ T-cells and neutrophils in
mdx muscles were unaffected by transplantation of CD11b/LIF
BMCs (Fig. 3k, l), indicating a selective reduction of M2-biased
macrophages caused by transgenic BMDCs.
LIF reduces Ccl2 expression in muscle and macrophages. The
large reductions of M2-biased macrophages in dystrophic muscle
of mice transplanted with CD11b/LIF BMCs (Fig. 3) suggest that
LIF inhibits their recruitment. Because abrogation of
CCR2 signaling reduces macrophage accumulation in dystrophic
muscle27, we tested whether CCR2 signaling was affected by LIF.
QPCR assays showed reduced expression of Ccr2 and its ligands
Ccl2, Ccl8 and Ccl12 in muscles of CD11b/LIF BMT recipients,
and a strong trend for lower levels of Ccl7 expression (P= 0.06)
(Fig. 4a).
We next tested the possibility that LIF acts directly on
macrophages to inhibit CCR2 signaling in vitro. Unexpectedly,
brief periods of macrophage stimulation with LIF had no effect on
Ccr2 expression and extended periods significantly increased Ccr2
expression (Fig. 4b). We assayed whether the CD11b/LIF
transgene affected the numbers of intramuscular macrophages
that expressed detectible CCR2 but found that the proportion of
CD68+ or CD206+ macrophages that expressed CCR2 was not
influenced by the transgene (Fig. 4c, d). This indicates that
reductions in macrophage-derived CCR2 in muscles reflect
reductions in macrophage numbers, rather than ablating the
expression of CCR2 in macrophages in CD11b/LIF BMT
recipients. However, stimulation of BMDMs with LIF reduced
Ccl2 expression and CCL2 protein secretion (Fig. 4e, f), indicating
that LIF acts directly on macrophages to negatively regulate Ccl2.
In addition, F4/80+ macrophages were prominent sources of
CCL2 in mdx muscle (Fig. 4g), and transplantation of CD11b/LIF
BMCs reduced the proportion of F4/80+ macrophages that
expressed detectible CCL2 by 15% (Fig. 4h).
Transplanted CD11b/LIF cells reduce muscle fibrosis. Fibrosis
of dystrophin-deficient muscle is largely driven by arginine
metabolism by arginase expressed by M2-biased macrophages23.
Arginine hydrolysis by arginase produces metabolites that are
utilized to generate substrate molecules necessary for connective
tissue production28. Because we observed reductions in M2-
biased macrophages in muscles of mdx mice that were recipients
of CD11b/LIF BMT and lower levels of expression of Arg2, we
assayed whether fibrosis was affected. Transplantation of CD11b/
LIF BMCs reduced collagen types 1, 3, and 5 in mdx muscle by
~41%, 22%, and 25%, respectively, compared to WT BMT reci-
pients (Fig. 5a–i). However, the anti-fibrotic effect of CD11b/LIF
BMT cannot be solely attributed to reductions of arginine
metabolism by M2-biased macrophages. QPCR data showed that
mRNA levels of collagen types 1 alpha 1 (Col1a1), 3 alpha 1
(Col3a1), and 5 alpha 3 (Col5a3) were reduced by ~57%, 51%,
and 30%, respectively, in CD11b/LIF BMC recipients (Fig. 5j),
indicating treatment effects on fibrogenic cells, in addition to
effects on macrophages that provide substrate for fibrogenesis.
M2-biased macrophages can act directly on fibrogenic cells
through TGFβ which activates fibro/adipogenic progenitor cells
(FAPs) into fibroblasts and stimulates fibroblasts to produce
collagen29–32. TGFβ can also activate Wnt-signaling, which
increases myogenic-to-fibrogenic conversion of muscle stem cells,
further contributing to dystrophic muscle fibrosis33. We tested
whether the CD11b/LIF BMT affected key transcripts of the Wnt
and TGFβ pro-fibrotic pathways. Although there was no effect on
the expression of Tgfb1 or Axin2, a Wnt-target gene (Fig. 5k), the
expression of downstream TGFβ target genes connective tissue
growth factor (Ctgf), fibronectin (Fn1), and snail family zinc
finger 1 (Snai1)34–37 were reduced by ~33%, 43%, and 33%,
respectively (Fig. 5k).
Fig. 2 CD11b/LIF transgene expression modulates inflammation and reduces fibrosis. a QPCR data showing Lif expression in muscles of CD11b/LIF
transgenic mdx mice (LIF/mdx) and non-transgenic littermates (WT/mdx), normalized to WT/mdx. TA muscles: n= 10. Diaphragm muscles: n= 8 or 7 for
WT/mdx and LIF/mdx data sets, respectively. * Indicates significant difference versus WT/mdx (P < 0.05). For all histograms, bars indicate mean ± sem. b,
c Cross-sections of WT/mdx (b) and LIF/mdx (c) TA muscles labeled with anti-LIF. Bars= 50 μm. d Mean fluorescence intensity (MFI) of inflammatory
lesions in sections immunolabeled for LIF. * Indicates significant difference from WT/mdx (n= 4; P < 0.05). e–j Cross-sections of muscles from WT/mdx
and LIF/mdxmice were immunolabeled with antibodies to F4/80 (e) and CD163 (h). Numbers of F4/80+ (f, g) and CD163+ (i, j) cells were normalized to
muscle volume. Labeling of F4/80+ (e) and CD163+ (h) cells in TA muscle from 1-month-old WT/mdx muscle. Bars= 100 μm. N= 5 for each group,
except n= 4 for F4/80 WT/mdx 1- and 12-month TA, LIF/mdx 12-month TA, WT/mdx 1- and 3-month diaphragm, and CD163 WT/mdx 12-month TA data
sets. k–p Cross-sections of TA (k, i) and diaphragm (n, o) muscles from 12-month-old WT/mdx (k, n) and LIF/mdx (l, o) mice were immunolabeled with
anti-collagen type 1. Bars= 50 μm. The volume fraction of muscle occupied by collagen type 1 (m, p). N= 5 for each group, except n= 4 for 3-month TA. *
Indicates significant difference versus age-matched WT/mdx mice (P < 0.05). # and Φ indicate significant difference versus 1- and 3-months-old,
genotype-matched mice, respectively (P < 0.05). P-values based on two-tailed t-test. q–s The passive mechanical properties of TA muscles of WT/mdx
(curves 1 and 2) and LIF/mdx (curves 3–5) mice were measured in-situ. Lissajous curves (q) show passive stiffness (r) and energy dissipation (s) of TAs.
N= 2 and 3 for WT/mdx and LIF/mdx groups, respectively. * Indicates significant difference versus WT/mdx mice. P-values based on two-tailed t-test.
Source data are provided as a Source Data file
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Fig. 3 Transplantation of CD11b/LIF transgenic BMCs into mdx mice reduces inflammation in dystrophic muscle. a QPCR analysis shows that the
transplantation of CD11b/LIF transgenic BMCs into mdx recipients (LIF BMT/mdx) reduced expression of transcripts associated with M2-biased
macrophages (Cd163, Cd206, and Arg2), Th2 cytokines (Il4 and Il10), and increased expression of the negative regulator of cytokine signaling (Socs3)
compared to WT BMT mdx recipients (WT BMT/mdx) 4 months post-transplantation. N= 7 or 8 for WT BMT/mdx and LIF BMT/mdx data sets,
respectively, except n= 7 for LIF BMT/mdx Arg1 data set. * Indicates significantly different from WT BMT/mdx recipients at P < 0.05. F-test Ifng (P=
0.0145), Il6 (P < 0.0001), Il4 (P= 0.0015), Il10 (P < 0.0001), and Socs3 (P= 0.0061). For all histograms in the figure, the bars indicate mean ± sem. b–j
Cross-sections of TA muscles fromWT BMT/mdx (c, f, i) or LIF BMT/mdx (d, g, j) mice were immunolabeled with antibodies to F4/80 (c, d), CD163 (f, g),
and CD206 (i, j). Bars= 50 μm. The numbers of F4/80+ (b), CD163+ (e), and CD206+ (h) cells normalized to muscle volume were reduced in LIF BMT/
mdx recipients. Similarly, cross-sections were immunolabeled with antibodies to CD4 and Ly-6B.2 (neutrophils) to test for changes in the concentrations of
other populations of immune cells. There was no change in the concentrations of CD4+ (k) and Ly-6B.2+ (l) cells. N= 5 for each data set, except n= 4 for
CD206 LIF BMT/mdx data set. * Indicates significantly different from WT BMT/mdx recipients at P < 0.05. All P-values based on two-tailed t-test. Source
data are provided as a Source Data file
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LIF reduces macrophage TGFβ1 expression. Although we
observed no effect of CD11b/LIF BMT on Tgfb1 mRNA in whole
muscle homogenates, we assayed more specifically for effects on
TGFβ expression in intramuscular macrophages by assaying the
proportion of macrophages that expressed TGFβ. We found that
there were 17.7% fewer intramuscular macrophages that expres-
sed detectible TGFβ in CD11b/LIF recipients, compared to WT
recipients (Fig. 6a). Interestingly, the greatest reduction of TGFβ
expressing macrophages was seen in inflammatory lesions of
CD11b/LIF recipients (Fig. 6c) compared to WT recipients
(Fig. 6b).
We tested whether reduced TGFβ1 expression in CD11b/LIF
BMT recipients reflected direct actions of LIF on macrophages to
inhibit TGFβ1 expression. When we treated BMDMs with LIF for
24 h, Tgfb1 gene expression was reduced by 47% and secreted
TGFβ protein expression by 29% (Fig. 6d, e), showing that LIF is
a negative regulator of TGFβ1 expression in macrophages.
However, Tgfb1 gene expression was not reduced after 3 h of
LIF stimulation, suggesting that LIF-mediated inhibition of Tgfb1
could be a secondary effect.
LIF reduces fibrogenesis and Ctgf mRNA in muscle cells. TGFβ
signaling promotes the fibrogenic conversion of myogenic cells in
dystrophic muscle, thereby contributing to fibrosis33. Because
transplantation of CD11b/LIF BMCs into mdx mice reduces
fibrosis, we tested whether LIF reduces the proportion of myo-
genic cells acquiring a fibrogenic phenotype. Muscle sections that
were double-labeled with anti-Pax7, a marker of satellite cells, and
anti-HSP47, a collagen-specific molecular chaperone38,39 showed
that the proportion of Pax7+ cells that expressed HSP47 was
reduced by 27.8% in CD11b/LIF recipients (Fig. 7a–c); this
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c, d Muscle sections co-labeled with antibodies to CD68 (c) or CD206 (d) and CCR2 show no change in the proportions of cells co-expressing CCR2
between transplant recipient groups. N= 5 for each data set. e QPCR analysis shows reduced Ccl2 gene expression in BMDMs stimulated with LIF as
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expressing CCL2 was reduced in LIF BMT/mdx recipients. N= 5 for each data set, * indicates significantly different from WT BMT/mdx recipients at P <
0.05. P-values based on two-tailed t-test. Source data are provided as a Source Data file
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indicates that satellite cells had a less fibrogenic phenotype in
CD11b/LIF recipients. Expression of Serpinh1, the gene that
encodes HSP47, was also reduced 24% in the whole muscle lysate
of CD11b/LIF recipients (mean ± sem: WT BMT/mdx 1 ± 0.08
and LIF BMT/mdx 0.76 ± 0.06, n= 7 and 8 per data set, respec-
tively, P= 0.03; two-tailed t-test). We also assayed whether
transplantation of CD11b/LIF BMCs affected the proportion of
satellite cells that expressed ERTR7 in vivo. ERTR7 was chosen in
addition to HSP47 because satellite cells in injured and aging
muscle that display elevated levels of ERTR7 expression have
shifted away from a myogenic phenotype, toward a fibrogenic
phenotype40,41. Our data show that the transgene reduced the
proportion of satellite cells that expressed ERTR7 in mdx muscle
in vivo, similar to the reduction of satellite cells expressing HSP47
(Fig. 7c, d).
We also tested whether the CD11b/LIF transgene affected the
phenotype of myogenic progenitor cells (MPCs) in later stages of
mdx pathology by assaying for changes in the expression of
fibrogenic genes in MPCs that were freshly-isolated from muscles
of 14-months-old mice. MPCs (CD11b-CD31-CD45-Sca1-α7
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integrin+ cells) from CD11b/LIF transgenic mdx mice showed
lower expression levels of Fn1 and Col3a1 compared to non-
transgenic mice (Supplementary Fig. 5). In addition, we observed
strong trends for the reduction in expression of Serpinh1 (HSP47)
and Col1a1 in freshly-isolated MPCs.
We also examined the effects of LIF on TGFβ1-induced muscle
cell fibrogenesis in vitro. We assayed myoblasts and myotubes
treated with TGFβ1 and/or LIF for changes in expression of
fibrogenic genes downregulated in CD11b/LIF BMT recipients
(Ctgf, Fn1, and Col1a1; Fig. 5j, k). Co-stimulation with TGFβ1
and LIF inhibited Ctgf expression, compared to cells treated with
TGFβ1 only (Fig. 7e, h). LIF also reduced basal Ctgf expression
after 24 h of stimulation in myotubes. Fn1 expression was stable
in myoblasts treated with TGFβ1, LIF, or TGFβ1+ LIF for 3 h
(Fig. 7f). After 24 h, TGFβ1-induced Fn1 expression, but co-
stimulation with LIF had no effect (Fig. 7i). TGFβ1 stimulation
for 3 h induced the expression of Col1a1 in myotubes, and LIF
attenuated TGFβ1-induced expression of Col1a1 in myotubes
(Fig. 7g). LIF stimulation for 24 h reduced basal Col1a1
expression in myoblasts, but not TGFβ1-induced expression of
Col1a1 (Fig. 7j).
LIF reduces the prevalence of FAPs in dystrophic muscle.
Because FAP-derived fibroblasts are important sources of con-
nective tissue proteins, we assayed whether CD11b/LIF BMT
affected FAP numbers in vivo or whether LIF affected the
expression of fibrogenic proteins by FAP-derived fibroblasts
in vitro. QPCR analysis showed that CD11b/LIF BMT recipients
had a 47% reduction in Pdgfra expression (Fig. 8a) which could
reflect fewer FAPs. Recipients of CD11b/LIF BMT had fewer cells
that expressed PDGFRα and were double-negative for CD31 and
CD45, which are FAPs42 (Fig. 8b, c), although the proportion of
PDGFRα+ cells that expressed HSP47 was unaffected by the
transgene (Fig. 8d). The findings indicate that reductions in
numbers of FAPs in the muscles of mdx mice receiving CD11b/
LIF BMT may contribute to reduced muscle fibrosis.
We then tested whether LIF influenced the fibrogenic activity
of FAP-derived fibroblasts in vitro. We sorted FAPs (CD11b/31/
45- PDGFRα+) fromWT muscles (Fig. 8e) and subcultured them
prior to stimulation with TGFβ1, LIF, or TGFβ1+ LIF41,42. We
used fibroblasts derived from FAPs rather than freshly-isolated
FAPs because fibroblasts differentiated from FAPs are the
primary source of connective tissue proteins in muscle32. We
tested if LIF affected Pdgfra expression in fibroblasts in vitro
because enhanced PDGFRα signaling can cause pathological
fibrosis43. However, LIF did not affect Pdgfra expression in
fibroblasts (mean ± sem: control cells 1 ± 0.04 and LIF-treated
cells 1.13 ± 0.23, n= 4 per data set, P= 0.61; two-tailed t-test).
Treatments for 3 h with TGFβ1-induced Ctgf expression in
fibroblasts, but LIF had no effect on basal or TGFβ1-induced Ctgf
(Fig. 8f). The magnitude of TGFβ1-induced Ctgf expression in
fibroblasts (1.9-fold) was less than in myoblasts (~11.6-fold) and
myotubes (~7.1-fold) (Fig. 7e). TGFβ1, LIF or TGFβ1+ LIF had
no effect on Fn1 or Col1a1 expression in fibroblasts (Fig. 8g, h).
We then tested whether prolonged stimulation of fibroblasts with
TGFβ1, LIF, or TGFβ1+ LIF affected Ctgf, Fn1, or Col1a1
expression. Similar to effects of brief stimulations, Ctgf expression
was induced ~2.0-fold by TGFβ1 but the induction was not
affected by LIF. There was also no effect of prolonged stimulation
with TGFβ1 on the expression of Fn1 or Col1a1 (Fig. 8i–k).
Transplanted CD11b/LIF cells do not affect muscle growth.
Because changes in macrophage phenotype and numbers influ-
ence muscle regeneration and myogenesis14,44–47, we assayed
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whether regeneration was affected in CD11b/LIF BMT recipients.
There were no significant differences in TA muscle weight, total
muscle fiber number, proportions of regenerating fibers or muscle
fiber size (Fig. 9a–d). No muscle fibers expressed dMHC in WT
BMT/mdx or LIF BMT/mdx mice. Additionally, QPCR assays
showed no effect of CD11b/LIF on expression of the myogenic
transcription factors: Pax7,Myod1,Myog, orMrf4 (Fig. 9e). These
data indicate that the CD11b/LIF transgene did not influence
processes through which immune cells modulate regeneration in
mdx muscle.
Discussion
The results of our investigation demonstrate that transplantation
of genetically-modified BMCs provides a means to deliver ther-
apeutic molecules to dystrophic muscle. In addition, by regulating
the expression of the therapeutic transgene with the CD11b
promoter, LIF delivery can be modified by the stages of
maturation and activation of innate immune cells that differ-
entiate from BMCs. This strategy provides a mechanism for the
endogenous regulation of transgene expression by the transplant
recipients that is responsive to the magnitude and site of
inflammation. This system also permits long-term delivery of
therapeutic molecules following a single therapeutic intervention.
Although tissues were analyzed 4 months following transplanta-
tion in the present investigation, at that time circulating leukocyte
populations were nearly 87% donor-derived. However, in humans
experiencing BMT, stable mixed chimerism can persist for years
in peripheral blood cell populations48,49, showing that long-term
benefits to humans can result from a single transplantation.
The potential therapeutic advantage of targeting therapeutic
molecules to diseased tissue by using transgenes under control of
the CD11b promoter is emphasized by comparing our findings
with the outcomes of previous strategies to deliver LIF via
hematopoietic cell transplantation. Transplantation of a hema-
topoietic cell line in which the cells were multiply-transduced
with a retroviral construct containing cDNA encoding LIF pro-
duced high systemic levels of LIF and killed the recipient
mice50,51. In those experiments the retrovirus-transplant reci-
pients reached serum LIF concentrations at 1400 units/ml,
although serum LIF was undetectable in mice transplanted with
cells that did not contain the LIF expressing retrovirus50,51. This
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contrasts with the delivery system we employ, in which elevated
LIF production was detectible within inflammatory lesions in
dystrophic muscle and pathology was reduced, but LIF remained
undetectable in the sera. This indicates that more precise tem-
poral and spatial delivery of LIF is necessary for safe and bene-
ficial therapeutic application.
Exogenous LIF has been reported previously to increase the
growth of dystrophic muscle fibers19,20, but we did not observe an
effect of the CD11b/LIF transgene on muscle mass or fiber size in
transgenic mice or in CD11b/LIF BMT recipients. These differ-
ences in outcome may reflect the different modes of LIF delivery,
in which increased fiber size resulted from continuous delivery of
high concentrations of exogenous LIF19,20. However, we found
that transplantation of CD11b/LIF transgenic BMCs affected mdx
muscle by decreasing muscle fibrosis, consistent with the treat-
ment effect achieved by delivery of exogenous LIF19,20,52. In part,
the anti-fibrotic influences of the CD11b/LIF transgene were
attributable to modifying the phenotype of satellite cells, reflected
in the reduced proportion of satellite cells that expressed detec-
tible levels of the collagen chaperone, HSP47, and expressed
ERTR7, a connective tissue protein expressed by pro-fibrotic
satellite cells40. This is functionally important in the context of
DMD pathology because the transition of satellite cells from an
HSP47−/ERTR7− to an HSP47+/ERTR7+ phenotype reflects a
reduction in their myogenic capacity and an increase in their
production of connective tissue proteins that may exacerbate the
pathology of muscular dystrophy33 and lead to a reduction in the
regenerative capacity of muscle over time40.
Although the CD11b/LIF transgene reduced the expression of
pro-fibrotic molecules by muscle cells in CD11b/LIF BMT reci-
pients in vivo, LIF did not reduce the basal level of expression of
genes encoding connective tissue proteins by muscle cells in vitro.
Instead, we found that LIF reduced the activation of pro-fibrotic
genes in myoblasts that was induced by the cytokine TGFβ. TGFβ
has broad, profibrotic effects by increasing the expression of
major, connective tissue proteins, including collagen and
fibronectin53,54, and reductions in TGFβ can significantly
decrease fibrosis of dystrophin-deficient muscle, at least at early
stages of the disease1,2,29. In addition to increasing the production
of connective tissue proteins, TGFβ can also influence muscle
fibrosis by promoting the differentiation of myofibroblasts from
muscle55,56 and by increasing the expression of other profibrotic
growth factors, especially CTGF53,54. Our finding that LIF
reduced or prevented the TGFβ-mediated induction of Ctgf
expression in muscle cells may be particularly significant in mdx
pathology because reductions in Ctgf expression can significantly
slow pathology57. Thus, our in vitro and in vivo data collectively
indicate that increases in LIF diminish fibrosis of dystrophic
muscle by opposing the profibrotic influence of TGFβ on
muscle cells.
The observation that the CD11b/LIF BMT reduced TGFβ1
expression in intramuscular macrophages without causing
reductions in total TGFβ1 expression in whole muscle also
indicates the specificity of targeting treatment effects that are
achieved by the CD11b/LIF transgene. This may provide advan-
tages over other experimental and therapeutic approaches that
have been explored previously to reduce fibrosis of dystrophic
muscle by inhibiting TGFβ1 expression or activity through
pharmacological approaches1,3,58,59. While those pharmacologi-
cal approaches are technically straight-forward and effective at
reducing fibrosis in dystrophic muscle, their systemic adminis-
tration does not provide delivery specifically to sites of inflam-
mation, and increases the risks of off-target effects.
Although CD11b/LIF BMT reduced pathological changes in
satellite cells, we found that some beneficial effects of CD11b/LIF
transgenic cells are attributable to modulation of the inflamma-
tory response, rather than direct actions on muscle (Fig. 10).
Despite the fact that DMD and mdx dystrophy result from
mutations that cause loss of the membrane-associated structural
protein, dystrophin, and lead to a mechanically-weaker muscle
cell membrane60,61, most muscle fiber damage results from lysis
caused by myeloid cells, especially macrophages expressing
inducible nitric oxide synthase (iNOS) that are biased toward the
M1, pro-inflammatory phenotype7,26. However, as the disease
progresses, macrophages in dystrophic muscle shift to a CD163
+/CD206+ phenotype that increases muscle fibrosis23 and is
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characteristic of type 2 immunity; much of the lethality of DMD
is attributable to fibrosis of cardiac and respiratory muscles. Thus,
by modulating the numbers and phenotype of macrophages in
dystrophic muscle, LIF can produce broad effects on muscle
pathology.
Some of the immunomodulatory effects achieved by trans-
plantation of CD11b/LIF transgenic cells reflect the effects of
transgene expression within the diseased muscle. For example,
Socs3 expression was significantly elevated in muscles of mice that
received CD11b/LIF BMT, although expression of the transgene
in macrophages in vitro did not affect the expression of Socs3. LIF
can increase Socs3 expression in multiple cell types62 and elevated
expression or activity of Socs3 in macrophages can strongly
influence their phenotype and cytokine production. In vivo
models of inflammation show that siRNA-silencing of SOCS3 or
targeted deletion of SOCS3 in macrophages can either promote63
or oppose64 the M1-biased phenotype. In experimental perito-
nitis, SOCS3 mRNA silencing in macrophages caused elevated
expression of the M2 phenotypic markers Il10, Mrc1, and Arg164,
which is consistent with the inverse relationship we observed
between elevated Socs3 expression in CD11b/LIF BMT recipients
and reduced expression of Il10, Arg2, and Mrc1. Together, these
observations suggest that the shift of CD11b/LIF macrophages
away from an M2-biased phenotype in mdx BMT recipients may
result, in part, from LIF induction of Socs3 after the transgenic
macrophages enter the diseased muscle. However, some of the
treatment effects that we observed may have resulted from
immunomodulatory roles of the transgene that occurred before
their invasion into the pathological muscle. Our finding that
isolated BMCs from CD11b/LIF mice showed greatly reduced
levels of Cd163 and Arg1 expression as they differentiated to
macrophages in vitro shows that some autocrine influences of the
transgene on macrophage gene expression do not require locali-
zation of the cells in the dystrophic muscle. This contrasts with
the reduced expression of TGFβ in intramuscular macrophages of
CD11b/LIF BMT recipients that did not occur in transgenic
macrophages in vitro. The reduction in arginase expression in
CD11b/LIF transgenic macrophages may be particularly impor-
tant in the pathophysiology of muscular dystrophy because
arginine metabolism by arginase increases proline production
which is necessary for collagen synthesis and contributes sig-
nificantly to increased fibrosis in mdx muscles during progressive
stages of pathology23.
The immunomodulatory influences of the transgene extend
beyond autocrine effects on macrophage phenotype, because the
muscles of CD11b/LIF BMC recipients showed large reductions
in the expression of ligands for CCR2. Previous investigators
established that signaling through CCR2 is a primary mechanism
for recruiting macrophages to diseased or injured muscle by
showing that blockade or deletion of CCR2 greatly reduces
macrophage entry into injured muscle27,45,47. We found that
CD11b/LIF BMT decreased expression of CCR2 ligands in muscle
and reduced the numbers of macrophages that expressed CCL2.
Those reductions were also associated with large reductions in
total numbers of F4/80+ intramuscular macrophages, including
CD206+ and CD163+ macrophages. Thus, much of the anti-
inflammatory effect of the transgene may occur through disrup-
tion of CCR2-mediated signaling, leading to reduced numbers of
intramuscular macrophages and impairing their activation to a
pro-fibrotic, M2-biased phenotype.
Collectively, our findings show that expression of a CD11b/LIF
transgene in BMDCs can disrupt multiple processes that con-
tribute to fibrosis of dystrophic muscle, including affecting
macrophage recruitment, phenotype and production of pro-
fibrotic cytokines and enzymes, in addition to preventing the
fibrogenic conversion of satellite cells and reducing numbers of
FAPs (Fig. 10). However, we believe that the more broadly-
significant finding in our investigation is that our data show that
genetically-modified BMCs can be used as vectors to deliver
therapeutic genes to dystrophic muscle. This approach is
applicable not only to LIF, but may provide a more specific tar-
geting strategy for the numerous gene products that have been
previously identified as potentially-useful, therapeutic molecules
for DMD.
Methods
Mice. All experimentation complied with all relevant ethical regulations for animal
testing and research, and the study protocol was approved by the Chancellor’s
Animal Research Committee at the University of California, Los Angeles. C57BL/
10ScSn-Dmdmdx/J mice (mdx mice) were purchased from The Jackson Laboratory
(Bar Harbor, ME) and bred in pathogen-free vivaria. Mdx mice were selected for
use in these experiments instead of more rapidly progressive models of DMD
because the goal of our investigation is to test our hypothesis that transplantation
of genetically-modified BMCs provides a novel therapeutic strategy for muscular
dystrophy. If we used a rapidly, progressive mouse model, such as the mdx/utr−
mouse line in which the mice die at 2–3 months of age, we would be unable to
assay for treatment effects achieved by bone marrow transplantation because the
mice would die before enough time passed for sufficient BMC engraftment and
then for the transplanted cells to mediate their therapeutic effects.
In preparation for generating CD11b/LIF mice, the complete Mus musculus LIF
cDNA sequence (611-bp; NM_008501) was amplified by PCR and ligated into a
pGL3-Basic vector (Promega) at the Nco I/Xba I sites. The pGL3-Basic vector
contained a 550-bp fragment of the human CD11b promoter at the Hind III site,
upstream of the LIF insertion site. The 1215-bp, hCD11b/LIF fragment was isolated
from pGL3-Basic by restriction endonuclease digestion with Xho I/Xba I and used
for pronuclear injection into CB6F1 eggs to generate transgenic mice. Positive
founders were identified by PCR screening for presence of the hCD11b/LIF
construct and backcrossed with C57BL/6J mice for 7 generations. The hCD11b/LIF
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Fig. 10 Potential immunomodulatory and anti-fibrotic actions of LIF expressed by the CD11b/LIF transgene in muscular dystrophy. (1) LIF can serve an
immunomodulatory role by reducing the expression of Ccl2 in macrophages, which is associated with reduced recruitment of monocytes/macrophages into
dystrophic muscle. (2) LIF can serve an immunomodulatory role by reducing the activation of monocytes/macrophages to a CD163+, M2-biased
phenotype that can increase fibrosis of dystrophic muscle. (3) LIF can reduce the expression of the pro-fibrotic molecules Arg1 and Tgfb1 in macrophages.
(4) LIF can reduce the TGFβ1-mediated induction of pro-fibrotic genes in muscle cells, including Ctgf and Col1a1
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line is maintained as hemizygous to produce transgenic mice and wild-type,
littermate controls for experimentation. Mice were randomly allocated to
experimental groups. WT or CD11b/LIF BMCs were transplanted into mdx mice
assigned non-sequential identification numbers. Investigators collecting data and
performing analysis were aware of animal numbers only and were blinded to
treatment groups.
CD11b/LIF mdx transgenic mice were produced by crossing CD11b/LIF
hemizygous males with mdx females to generate CD11b/LIF hemizygous,
transgenic mice that were also dystrophin-deficient (CD11b/LIF mdx). Dystrophin-
deficient status was verified by ARMS PCR screening65 and presence of the
hCD11b/LIF construct was determined as described above. The CD11b/LIF mdx
mice were backcrossed with wild-type mdx mice for 7 generations to produce
CD11b/LIF mdx mice that were dystrophin-deficient and either hemizygous or
wild-type controls for the CD11b/LIF transgene.
Bone marrow transplantation. Beginning 1 week prior to BMT, mouse drinking
water was supplemented with trimethoprim/sulfamethoxazole (80 μg/ml tri-
methoprim and 400 μg/ml sulfamethoxazole) and continued for 3 weeks. Two-
month-old female mdx mice underwent myeloablative preconditioning via intra-
peritoneal injections of 1,4-butanediol dimethanesulfonate (Sigma-Aldrich) (20
mg/kg body weight) 72-, 48-, and 24-h prior to BMT. On the day of transplan-
tation, male WT and CD11b/LIF donor mice were euthanized and their femur and
tibia bones were sterilely dissected and flushed of BMCs. BMCs were isolated and
recipient mice received 107 donor BMCs by tail-vein injection. At 4 months post-
BMT, tissues and BMCs were collected from recipient mice. BMCs were used for
chimerism analysis by fluorescent in situ hybridization of the Y-chromosome
(Kreatech FISH Probes).
RNA isolation and QPCR. RNA was isolated from muscle homogenates and
reverse transcribed to produce cDNA24. QPCR experiments were designed using
established guidelines for experimental design, data normalization and data ana-
lysis to maximize the rigor of quantifying the relative levels of mRNA13,66,67. The
expression for each gene in control samples was set to 1 and the other expression
values were then scaled to that value. PCR primers are listed in Supplementary
Table 1.
Cultured cells were washed twice with ice-cold DPBS and collected in Trizol
(Invitrogen). RNA was extracted and isolated with chloroform extraction and
isopropyl alcohol precipitation, followed by clean-up with an RNA Clean and
Concentrator Kit (Zymo Research). Total RNA was quantified, reverse transcribed,
and used for QPCR13.
RNA was isolated from FACS sorted cells by first sorting cells directly into
Buffer RLT RNA lysis buffer (Qiagen). RNA was isolated using a Qiagen RNeasy
Micro Kit according to the manufacturer’s protocol. RNA yield was quantified
using a BioDrop μLite. RNA (50 ng/reaction) was reverse transcribed using a
qScript XLT cDNA Supermix (QuantaBio). QPCR experiments were performed on
a QuantStudio 5 Real-Time PCR System (Thermo Fisher) with PerfeCTa SYBR
Green Supermix, Low Rox (QuantaBio)13.
Immunohistochemistry. Muscles dissected from euthanized mice were frozen in
liquid nitrogen-cooled isopentane. Cross-sections 10-µm thick were taken from the
mid-belly of muscles and fixed in ice-cold acetone or 2% paraformaldehyde for 10
min. Endogenous peroxidase activity in the sections was quenched by immersion in
0.3% H2O2. Most sections were blocked for 1 h with blocking buffer (3% bovine
serum albumin (BSA), 2% gelatin, and 0.05% Tween-20 in 50 mM Tris–HCl pH 7.6
containing 150 mM NaCl). Alternatively, sections were incubated with 10% horse
serum in PBS with 0.1% Tween-20 or mouse-on-mouse blocking reagent (M.O.M.
kit; Vector) for sections to be incubated with primary antibodies from goat or
mouse origin, respectively. Sections were then incubated with: rat anti-mouse F4/80
(1:100, overnight at 4 °C, eBioscience, clone BM8), rat anti-mouse CD68 (1:100, 3 h
at room temperature (RT), AbD Serotec, clone FA-11), rabbit anti-mouse CD163
(1:100, 3 h at RT, Santa Cruz Biotech, clone M-96), rat anti-mouse CD206 (1:50, 3
h at RT, AbD Serotec, clone MR5D3), rat anti-CD4 (1:25, overnight at 4 °C,
Biolegend, clone GK1.5), rat anti-Ly-6B.2 (1:25, 2 h at RT, Bio-Rad, clone 7/4),
rabbit anti-collagen type 1 (1:50, 3 h at RT, Chemicon, #AB745), goat anti-collagen
type 3 (1:50, 3 h at RT, Southern Biotech #1330-01), goat anti-collagen type 5 (1:50,
overnight at 4 °C, Southern Biotech, #1350-01), goat anti-LIF (1:66, overnight at 4 °
C, R&D Systems, #AB-449), and mouse anti-developmental myosin heavy chain
(1:100, overnight at 4 °C, Novacastra, #106304). The sections were washed with
phosphate buffered saline (PBS) and probed with biotin-conjugated secondary
antibodies (1:200, 30 min at RT, Vector Laboratories). Sections were then washed
with PBS and incubated with avidin D-conjugated HRP (1:1000, 30 min at RT,
Vector). Staining was visualized with the peroxidase substrate, 3-amino-9-
ethylcarbazole (Vector).
Immunofluorescence. For co-labeling of macrophages, sections were fixed in ice-
cold acetone for 10 min and then incubated in blocking buffer for 1 h. Sections
were then incubated with rat anti-F4/80 and goat anti-CCL2 (1:50, R&D Systems,
AB-479-NA) or rabbit anti-TGFβ1 (1:100, Abcam, #ab92486) overnight at 4 °C.
Sections were washed with PBS and then incubated with donkey anti-rat Dylight
488 (1:200, 30 min at RT, Abcam, #ab102260) and horse anti-rabbit IgG Dylight
594 (1:200, 30 min at RT, Vector, #DI-1094) or horse anti-goat IgG Dylight 594
(1:200, 30 min at RT, Vector, #DI-3094). Sections were then washed with PBS and
mounted with Prolong Gold mounting media (Invitrogen).
For identification of CCR2+ macrophages, sections were fixed with 4% PFA for
10 min and then incubated with blocking buffer for 1 h. Sections were then labeled
with rabbit anti-mouse CCR2 (1:50, Abcam, clone E68) and rat anti-mouse CD68
or rat anti-mouse CD206 at 4 °C overnight. Sections were washed with PBS and
then incubated with donkey anti-rat IgG Dylight 594 (1:200, 30 min at RT, Abcam,
#ab102262) and horse anti-rabbit IgG Dylight 488 (1:200, 30 min at RT, Vector,
#DI-1088).
For identification of fibrogenic satellite cells, sections were fixed in 2%
paraformaldehyde for 10 min. Slides were then immersed in antigen retrieval buffer
(10 mM sodium citrate, 0.05% Tween-20, pH 6) at 95–100 °C for 40 min, except for
sections undergoing Pax7/Ertr7 co-labeling this step was omitted. Sections were
then treated with blocking buffer from a mouse-on-mouse immunohistochemistry
kit (M.O.M. kit; Vector) for 1 h and immunolabeled with mouse anti-Pax7 and
rabbit anti-HSP47 (1:200, Abcam, #77609) or anti-Ertr7 (1:1000, SCBT, #SC-
73355) overnight at 4 °C. Anti-Pax7 was purified from hybridoma cell supernatant
(Developmental Studies Hybridoma Bank, Iowa City, Iowa)68. Sections were
washed with PBS and then incubated with horse anti-mouse IgG Dylight 594
(1:200, 30 min at RT, Vector, DI-2594) and horse anti-rabbit IgG Dylight 488
(1:200, 30 min at RT).
For identification of FAPs, sections were fixed in ice-cold acetone for 10 min
and then incubated with blocking buffer for 1 h. Sections were then labeled with rat
anti-mouse CD31 conjugated with FITC (1:50, eBioscience, clone 390), rat anti-
mouse CD45 conjugated with FITC (1:100, eBioscience, clone 30-F11), and goat
anti-PDGFRα (1:100, R&D Systems, #AF1062) at 4 °C overnight. Sections were
washed with PBS and then incubated with horse anti-goat IgG Dylight 594 (1:200,
30 min at RT, Vector).
For identification of fibrogenic PDGFRα+ cells, sections were fixed in ice-cold
acetone for 10 min and then incubated with blocking buffer for 1 h. Sections were
then labeled with rabbit anti-mouse HSP47 (1:100, ABcam, clone EPR4217) and
goat anti-PDGFRα at 4 °C overnight. Sections were washed with PBS and then
incubated with horse anti-goat IgG Dylight 594 (1:200, 30 min at RT) and horse
anti-rabbit IgG Dylight 488 (1:200, 30 min at RT).
Stereology. The number of cells per volume of muscle was determined by mea-
suring the total volume of each section using a stereological, point-counting
technique to determine section area and then multiplying that value by the section
thickness (10 μm)7. The numbers of immunolabeled cells in each section were
counted and expressed as the number of cells per unit volume of each section.
Assays for fiber number, central nucleation, and size. TA muscles were sec-
tioned at the midbelly of muscles and used for fiber cross-sectional area mea-
surements5. The proportion of fibers containing central nuclei, an indicator of fiber
regeneration, was also determined. Central-nucleation was expressed as the ratio of
central nucleated fibers relative to the entire population of fibers sampled for each
muscle. The cross-sectional areas of >300 muscle fibers were measured using a
digital imaging system (BioQuant).
Assay of muscle connective tissue content. The volume fraction of muscle that
was occupied by collagen types 1, 3, and 5 was determined by overlaying a 10 × 10
eye-piece grid on microscopic images of cross-sections of entire muscle that were
immunolabeled with antibodies to collagen types 1, 3, or 5.
Preparation of BMMCs and BMDMs. BMMCs were separated from whole BMC
preparations flushed from WT or CD11b/LIF femurs and tibiae and separated
using a histopaque-1077 gradient (Sigma). The freshly-isolated BMMCs were then
used for RNA isolation and analysis. For preparation of BMDMs, BMCs were
aseptically flushed from WT or CD11b/LIF femurs and tibiae and differentiated
in vitro to BMDMs24. BMDMs were stimulated for 24 h with activation media
consisting of Dulbecco’s Modified Eagle Medium (DMEM) with 0.25% heat-
inactivated fetal bovine serum (FBS; Omega), 100 U/ml penicillin, 100 µg/ml
streptomycin (1% P/S), and 10 ng/ml macrophage colony stimulating factor
(MCSF; R&D).
ELISA analysis of BMDM conditioned media. Cultures of BMDM from WT mice
were established as described above. On the 6th day of culture, the BMDMs were
switched to DMEM containing 1% P/S, 0.25% heat-inactivated FBS, and M-CSF or
media containing 10 ng/ml recombinant mouse LIF (eBioscience) (stimulation
media). After 24 h of stimulation, conditioned media (CM) were collected, briefly
centrifuged to remove particulates and then frozen at −20 °C. Separate aliquots of
BMDM CM from each sample were analyzed for expression of CCL2 (Duoset
ELISA, R&D Systems, #DY479) and TGFβ (Emax immunoassay; Promega,
#G7590), according to manufacturer’s instructions. Following an HRP-based
reaction, a colored product was formed in proportion to the amount of cytokine
present, which was analyzed by a spectrophotometer (Bio-Rad Benchmark
Microplate Reader) at a wavelength of 450 nm with a 540 nm correction. The
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concentration of each cytokine was determined by comparing the optical density of
the samples to the standard curve.
ELISA analysis of serum. Whole blood was collected from the femoral artery and
allowed to clot on ice for at least 30 min. The whole blood was spun for 10 min at
2000×g at 4 °C. The serum was collected and stored in liquid nitrogen until ana-
lyzed for circulating LIF, TNFα, IFNγ, IL-4, and IL-10 by ELISA, according to
manufacturer’s instructions (R&D Systems, Quantikine ELISAs, #MLF00,
MTA00B, MIF00, M4000B, and M1000B). Each group contained 3 replicates.
Assays for LIF effects on muscle cell fibrogenesis. The C2C12 cell line was
purchased from American Type Culture Collection (ATCC CRL-1772 cell line).
The cells were authenticated as myoblasts by confirming their differentiation into
contractile myotubes that express characteristic muscle proteins. Cells were seeded
in six-well plates at 6 × 104 cells per well and cultured in DMEM containing 10%
FBS, 1% P/S at 37 °C in 5% CO2 for 24 h and then serum-starved overnight prior to
stimulation. To generate myotubes, myoblasts were grown to 90% confluence and
then differentiated in serum-free DMEM for 24 h. The cells were then returned to
DMEM containing 10% FBS for 5 days. Myoblast and myotube cultures were
stimulated with vehicle, TGFβ1 (10 ng/ml), LIF (10 ng/ml), or TGFβ1+ LIF for 3-
or 24-h.
FAPs and myogenic progenitor cell preparation and isolation. FAPs were iso-
lated from 6-month-old WT mice. Hindlimb and forelimb muscles were dissected
and rinsed in DMEM. Muscles were minced and digested in 5 ml of enzyme buffer
(DMEM, 25 mM HEPES (Sigma), 5 mM MgCl2 (Fisher), 2% P/S, 12.5 U dispase,
type II, 12.5 U collagenase B, and 20 μg/ml DNase I (Roche)) for 60 min at 37 °C
with gentle trituration. The digestion was neutralized with 2 volumes of staining
buffer (DMEM, 10 mM NaHCO3 (EMD Millipore), 25 mM HEPES, 5 mM EDTA,
5 mM MgCl2, 1 mM L-glutamine, 2% BSA, and 2% P/S). The digestate was passed
through 100 μm mesh filters and cells were pelleted at 350g for 5 min. Cells were
resuspended in ACK lysis buffer (Lonza) for 5 min followed by the addition of an
equal volume of staining buffer and cells were pelleted at 350g for 5 min. Cells were
resuspended in staining buffer with CD16/32 (eBioscience #14-0161-85; 0.5 µg/test)
for 10 min to block Fc receptor binding. Cells were labeled with Hoechst (Sigma
#14533) and antibodies against CD11b (eBioscience #11-0112; 0.25 µg/test), CD31
(eBioscience #11-0311; 0.5 µg/test) and CD45 (eBioscience #11-0451; 0.1 µg/test)
conjugated with FITC and PDGFRα conjugated with PE-Cy7 (eBioscience #25-
1401; 0.2 µg/test). FAPs (Hoechst+CD11b/31/45-PDGFRα+) were sorted into
collection buffer (DMEM, 10 mM NaHCO3 and 20% FBS) using a BD SORP
FACSAriaII cell sorter.
MPCs were isolated from 14-months-old CD11b/LIF mdx mice and littermate
controls. Hindlimb and forelimb muscles were dissected and digested as described
for FAPs isolation. Isolated cells were resuspended in staining buffer with CD16/32
for 10 min to block Fc receptor binding. Cells were labeled with cell impermeant
dye DAPI (Sigma) to distinguish live cells and antibodies against CD11b, CD31,
and CD45 conjugated with FITC and Sca-1 conjugated with PE-Cy5 (eBioscience
#15-5981; 0.2 µg/test), integrin α7 conjugated with PE (Medical and Biological
Laboratories #K0046-5; 15 µl/test). Live MPCs (DAPI-CD11b/31/45-Sca1-α7int+)
were sorted into Buffer RLT RNA lysis buffer (Qiagen) using a FACSAriaIII high
speed cell sorter.
Primary fibroblast cell culture. Sorted FAPs were cultured in growth medium
(DMEM, 20% FBS, 10% heat-inactivated horse serum, 1% P/S and 2.5 ng/ml bFGF)
on tissue culture plates coated with Matrigel41. After plating, cells were cultured for
3 days and half the medium was changed. Cells were expanded and subcultured.
Prior to stimulation, cells were cultured in reduced serum media overnight
(DMEM, 2% FBS, 1% P/S, and 2.5 ng/ml bFGF). Fibrogenic cell cultures were
stimulated with vehicle, TGFβ1 (10 ng/ml), LIF (10 ng/ml), or TGFβ1+ LIF for 3 h
or 3 days (with media changes at 24- and 48-h).
Physiological analysis. We assayed muscle stiffness and viscoelasticity at
14 months of age because connective tissue accumulation in mdx muscle is pro-
gressive between 3 and 24 months of age. We expected that if we sampled for
effects of the transgene on muscle stiffness during the late, progressive stage of the
disease, the magnitude of the effect would be greater, which would enable us to
address more definitively the question of whether the transgene influenced muscle
stiffness. Male WT/mdx and LIF/mdx mice were anesthetized by the intraper-
itoneal (i.p.) injection of ketamine (40 mg/kg body weight). Anesthesia was checked
by testing mice for a positive reflex response to a hind foot pinch and by mon-
itoring respiration. Additional i.p. injections of ketamine were given throughout
the study, as needed. For in-situ analysis of the TA muscle the knee was immo-
bilized to the heated (37 °C) platform of an 809C in-situ mouse apparatus (Aurora
Scientific). Silk sutures (5-0; Ethicon) were knotted to the distal, severed tendon
and then secured to the lever arm of a dual-mode force transducer-servomotor
(Aurora Scientific, Model 305C-5N). After placing platinum-tipped electrodes into
the leg above the knee, flanking the sciatic nerve, the TA muscle was stimulated by
pulses and manipulated on three axes to find the optimal muscle length (Lo). Lo
was multiplied by the pennation of 0.6 for the TA muscle69 to determine optimal
fiber length (Lf). To measure elasticity, the muscle was left unstimulated while the
lever arm oscillated at ±20% of the Lf for 20 s. Muscles were allowed to rest for 60 s
before subsequent oscillation series. Muscles were allowed to rest for 60 s before a
series of oscillations at 3 Hz, which provides a physiological strain and strain rate70.
Dynamic Muscle Control and Dynamic Muscle Analysis (Aurora Scientific) soft-
ware was used to conduct experiments and record data. Force measurements were
normalized to muscle cross-sectional area, and position measurements were nor-
malized to percent of Lf.
Statistical analyses. All data are presented as mean ± sem. Statistical significance
was calculated using unpaired Student’s t-tests or ordinary one-way ANOVA with
Tukey’s multiple comparison test to determine differences among multiple groups.
Differences with a P-value < 0.05 were considered statistically significant. The
equality of variance between the groups that are being compared was tested with an
F test, experiments with a P-value < 0.05 are denoted in the figure legend. Addi-
tionally, for immunohistochemistry and immunofluorescence experiments, slides
were only included if concurrently immunolabeled. Statistical analysis was per-
formed using GraphPad Prism.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
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